RELIEF THERAPEUTICS Holding SA

"Category: Notifications issued to company members/nSub-category: Invitation to the General Meeting/nPublication date: SHAB 24.10.2025/nPublicly viewable until: 24.10.2026/nPublication number: UP04-0000007482/nPublishing entity/nRELIEF THERAPEUTICS Holding SA, avenue de Sécheron 15.

1202 Genève/nInvitation to the extraordinary general meeting/nRELIEF THERAPEUTICS Holding SA/nOrganisation concerned:
/nRELIEF THERAPEUTICS Holding SA/nCHE-113.516.874/navenue de Sécheron 15/n1202 Genève/nGeneral meeting details:/n14.11.2025, 17.30 Uhr, Avenue de Sécheron 15.

1202 Genève/nInvitation/Agenda:
/n1. Ordinary capital increase/n2. Capital band/n3. Conditional capital/n4. Change of company name/n5. Amendment of corporate purpose/n6. Election of new members of the board of directors and of the chairman/n7. Election of new members of the nomination and compensation committee/nRELIEF THERAPEUTICS HOLDING SA/nwith seat in Geneva/nINVITATION TO THE EXTRAORDINARY GENERAL MEETING/nto be held on Friday, 14 November 2025.

at 5:
30 p.m. CET/n(doors open at 5:00 p.m.)/nat Avenue de Sécheron 15, 1202 Geneva, Switzerland/nin accordance with Article 9 et seq. of the Articles of Association/nAgenda/n1. Ordinary Capital Increase/n2. Capital Band/n3. Conditional Capital/n4. Change of Company Name/n5. Amendment of Corporate Purpose/n6. Election of New Members of the Board of Directors and of the Chairman/n7. Election of New Members of the Nomination and Compensation Committee/nInvitation from the Board of Directors/nDear Shareholders,/nThe Board of Directors of RELIEF THERAPEUTICS Holding SA (""Relief"" or the ""Company"") invites you to/nan Extraordinary General Meeting (the ""EGM"") to seek your approval for the proposed business/ncombination between Relief and NeuroX Group SA, a digital therapeutics company domiciled in/nLausanne, Canton of Vaud, and registered under no. CHE-324.977.766 (""NeuroX"")./nOn October 8, 2025, we publicly announced that we had entered into a binding transaction agreement/nwith NeuroX, which, subject to the fulfilment of the conditions set forth in the agreement, provides for/na business combination between Relief and NeuroX (the ""Transaction"")./nUnder the terms of this agreement, Relief will acquire all outstanding shares of NeuroX from the existing/nNeuroX shareholders by way of a contribution in kind, in exchange for newly issued Relief shares. Upon/nClosing of the Transaction, NeuroX's shareholders will receive a total of 140 million Relief shares, and/nRelief will increase its share capital by a corresponding amount, from currently approximately 14 million/noutstanding shares. For the purposes of this invitation, the term ""Closing"" refers to the completion of/nthe stock-for-stock exchange, pursuant to which the shareholders of NeuroX will contribute their shares/nto Relief in exchange for newly issued Relief shares./nThe proposed business combination represents a compelling and risk-balanced growth opportunity./nEarlier this year, NeuroX acquired strategic assets from MindMaze Group SA and MindMaze SA,/nestablishing the foundation of its business. The Transaction will create a publicly listed, AI-based/ntherapeutics platform integrating software-delivered, disease-modifying clinical interventions with/npharmacological treatments and a comprehensive brain health platform. NeuroX contributes a clinically/nvalidated and de-risked portfolio, supported by milestones achieved across technological development,/nregulatory approvals, and market access, as well as a network of pharmaceutical partners. Together, the/ncombined company will be uniquely positioned to advance precision neurology solutions and create/nsustainable value for shareholders./nThe Transaction remains subject to certain closing conditions, including the approval by Relief's/nshareholders of all proposals to be voted on at this EGM, followed by the approval of SIX Swiss Exchange/nfor the listing of the newly issued shares. We therefore invite all Relief shareholders to cast their votes/nin favor of all proposals, either by attending in person or by submitting a proxy vote./nWe would like to take this opportunity to thank all Relief shareholders for their continued confidence/nand support./nWith sincere thanks and best regards,/nThe Board of Directors/nRELIEF THERAPEUTICS Holding SA/nAGENDA, PROPOSALS AND EXPLANATIONS OF THE BOARD OF DIRECTORS/n1 ORDINARY CAPITAL INCREASE/nMotions/nThe Board of Directors proposes an ordinary capital increase as follows and the respective amendment of/nArticle 3 (Share Capital) of the Company's Articles of Association:/n(a) the share capital of the Company shall be increased by up to CHF 14,000,000 by issuing up to/n140,000,000 fully paid-up registered shares with a nominal value of CHF 0.10 each;
/n(b) the issue price shall be CHF 0.10 per share and shall be paid in through contributions in kind of/nexisting shares of NeuroX (1,000,000 registered shares with a nominal value of CHF 0.10 each);
/n(c) the pre-emptive rights of existing Relief shareholders are excluded for good cause. The Board of/nDirectors is authorized to allocate pre-emptive rights to some or all shareholders or to third parties,/nincluding third parties who have signed an agreement for the subscription and purchase of such/nshares to be issued;
/n(d) the new Relief shares shall be entitled to dividends as from the date of their issuance and shall be/nsubject to the restrictions on transferability in accordance with Article 5 of the Articles of/nAssociation./nThe resolution under this agenda item is conditional upon the EGM approving the proposals of the Board/nof Directors under agenda items 4, 5 and 6./nExplanations/nFor the purpose of effecting the proposed business combination with NeuroX, the Board of Directors/nproposes to increase the Company's share capital in order that shareholders of NeuroX receive newly/nissued shares of the Company in consideration of and by contributing their respective shares of NeuroX/nto the Company by way of contribution in kind, at a fixed exchange ratio of 140 Relief shares for each/nNeuroX share. Upon completion of the ordinary capital increase, NeuroX's shareholders are expected to/nown approximately 91.75% and Relief's existing shareholders approximately 8.25% of Relief's issued and/noutstanding share capital./nThis capital increase will be implemented and entered in the commercial register immediately prior to the/nClosing of the Transaction./nAccording to Swiss law and the Articles of Association, the proposed ordinary capital increase requires/napproval by two thirds of the votes and the majority of the nominal value of shares represented at the/ngeneral meeting./nIf the EGM approves the motion under this agenda item 1 but not the motions under agenda items 4, 5/nand 6, the capital increase resolved under this agenda item 1 will not be valid./n2 CAPITAL BAND/nMotions/nThe Board of Directors proposes (i) the introduction of a capital band from 100% of the share capital after/nimplementation of the capital increase pursuant to agenda item 1 (lower limit) to approximately 126% of/nthe share capital after implementation of the capital increase pursuant to agenda item 1 (upper limit),/ncorresponding to 40,000,000 potential additional shares, as replacement of the existing capital band/n(Article 3ater of the current Articles of Association);
the Board of Directors shall be authorized to increase/nthe share capital within the capital band once or several times and in any amounts until November 13,/n2030, or until an earlier expiry of the capital range and (ii) to delete and replace Article 3ater of the Articles/nof Association by a new Article 3ater as set out in the Annex with effect as of the completion of the ordinary/ncapital increase according to agenda item 1./nThe resolution under this agenda item is conditional upon the EGM approving the proposals of the Board/nof Directors under agenda items 1, 4, 5 and 6./nExplanations/nGenerally, a capital band may authorize the Board of Directors of a company to increase or reduce the/nshare capital within a certain range of the share capital registered in the commercial register at the time/nthe capital band is introduced. The author"

"Category: Notifications issued to company members/nSub-category: Invitation to the General Meeting/nPublication date: SHAB 16.05.2025/nPublicly viewable until: 16.05.2027/nPublication number: UP04-0000007196/nPublishing entity/nRELIEF THERAPEUTICS Holding SA, avenue de Sécheron 15.

1202 Genève/nInvitation to the ordinary general meeting RELIEF/nTHERAPEUTICS Holding SA/nOrganisation concerned:
/nRELIEF THERAPEUTICS Holding SA/nCHE-113.516.874/navenue de Sécheron 15/n1202 Genève/nGeneral meeting details:/n12.06.2025, 10.00 Uhr, Campus Biotech, avenue de Sécheron 15.

1202 Genève/nInvitation/Agenda:
/n1 Approval of the 2024 Annual Report, the Annual Statutory Financial Statements, and/nthe Annual Consolidated Financial Statements for the 2024 Financial Year/n2 Appropriation of Available Earnings/n3 Discharge of the Board of Directors and the Executive Committee/n4.1 Re-elections of the members of the Board of Directors/n4.2 Re-election of the Chairman of the Board of Directors/n4.3 Re-elections of the members of the Nomination and Compensation Committee/n5.1 Vote on the compensation of the Board of Directors/n5.2 Vote on the total compensation of the Executive Committee/n5.3 Consultative vote on the 2024 Compensation Report/n 6 Re-election of the Independent Voting Rights Representative/n 7 Re-election of the Auditors/n To the shareholders of RELIEF THERAPEUTICS Holding SA:/n Invita on to the Annual General Mee ng/n of RELIEF THERAPEUTICS Holding SA/n Thursday, 12 June 2025.

10:
00 a.m. CEST/n Avenue de Sécheron 15, 1202 Geneva, Switzerland/n The Annual General Mee ng (the ""General Mee ng"") of shareholders of RELIEF THERAPEUTICS Holding SA/n (the ""Company"") will be held in accordance with Ar cle 9 et seq. of the Ar cles of Associa on on Thursday,/n 12 June 2025.

at 10:
00 a.m. CEST, at Avenue de Sécheron 15, 1202 Geneva, Switzerland (doors open at/n 09:30 a.m.)./n Agenda and Proposals of the Board of Directors/n1. Approval of the 2024 Annual Report, the Annual Statutory Financial Statements, and the Annual/n Consolidated Financial Statements for the 2024 Financial Year/n The Board of Directors proposes that the General Mee ng approve the 2024 annual report, the statutory/n financial statements, and the consolidated financial statements for the 2024 financial year./n Explana on: Pursuant to ar cle 698 para. 2 items 3 and 4 of the Swiss Code of Obliga ons (""CO""), the/n General Mee ng is responsible for approving the annual report and the financial statements./n2. Appropria on of Available Earnings/n The Board of Directors proposes to carry forward the net result for the 2024 financial year of CHF 916'291,/n thereby bringing the accumulated loss to CHF 257'968'557./n Explana on: Pursuant to ar cle 698 para. 2 item 4 CO, the General Mee ng is responsible for the/n appropria on of available earnings./n3. Discharge of the Board of Directors and the Execu ve Commi ee/n The Board of Directors proposes that the General Mee ng grant discharge to all current and former/n members of the Board of Directors and the Execu ve Commi ee for the 2024 financial year./n Explana on: Pursuant to ar cle 698 para. 2 item 7 CO, the General Mee ng is responsible for the discharge/n resolu on./n4. Elec ons to the Board of Directors/n 4.1.

Re-elec ons of the members of the Board of Directors/n The Board of Directors proposes the individual re-elec on of all members of the Board of Directors for/n another term of office un l the conclusion of the next Annual General Mee ng, as follows:
/n a) Re-elec on of Dr. Raghuram Selvaraju/n b) Re-elec on of Mr. Gregory Van Beek/n c) Re-elec on of Mr. Peter de Svas ch/n d) Re-elec on of Mr.

Thomas Elzinga/n Explana on:
Pursuant to ar cle 698 para. 2 item 2 CO, the General Mee ng is responsible for the elec ons/n of the members of the Board of Directors. Biographical informa on is available in the 2024 annual report/n and on the Company's website./n 4.2. Re-elec on of the Chairman of the Board of Directors/n The Board of Directors proposes the re-elec on of Dr. Raghuram Selvaraju as Chairman of the Board of/n Directors for another term of office un l the conclusion of the next Annual General Mee ng./n Explana on: Pursuant to ar cle 698 para. 3 item 1 CO, the General Mee ng is responsible for the above/n elec on./n 4.3.

Re-elec ons of the members of the Nomina on and Compensa on Commi ee/n The Board of Directors proposes the individual re-elec on of the members of the Nomina on and/n Compensa on Commi ee for another term of office un l the conclusion of the next Annual General/n Mee ng, as follows:
/n a) Re-elec on of Mr. Peter de Svas ch/n b) Re-elec on of Dr.

Raghuram Selvaraju/n Explana on:
Pursuant to ar cle 698 para. 3 item 2 CO, the General Mee ng is responsible for the above/n elec on. The elec ons of the members of the Nomina on and Compensa on Commi ee are held/n individually./n5. Compensa on of the Board of Directors and the Execu ve Commi ee/n 5.1. Binding vote on the total compensa on of the members of the Board of Directors for the period/n from the 2025 Annual General Mee ng un l the 2026 Annual General Mee ng/n The Board of Directors proposes the approval of a maximum total compensa on of CHF 1'000'000 (fixed/n and variable components, including stock op ons and other benefits, excluding employer social security/n contribu ons) for the members of the Board of Directors for the period from this 2025 Annual General/n Mee ng un l the 2026 Annual General Mee ng./n Explana on: Pursuant to ar cle 698 para. 3 item 4 CO, the General Mee ng is responsible for approving/n the maximum compensa on of the Board of Directors. The compensa on of the Board of Directors is/n determined based on discre onary economic considera ons and may be delivered in cash and in the form/n of op ons. A descrip on of the Company's compensa on principles and amounts for the members of the/n Board of Directors can be found in the 2024 compensa on report./n 5.2. Binding vote on the total compensa on of the members of the Execu ve Commi ee for the 2026/n Financial Year/n The Board of Directors proposes the approval of a maximum total compensa on of CHF 2'000'000 (fixed/n and variable components, including stock op ons and other benefits, excluding employer social security/n contribu ons) for the members of the Execu ve Commi ee for the 2026 financial year./n Explana on: Pursuant to ar cle 698 para. 3 item 4 CO, the General Mee ng is responsible for approving the/n maximum compensa on of the Execu ve Commi ee. The compensa on of the members of the Execu ve/n Commi ee consists of fixed compensa on, poten al variable compensa on, and other benefits. A/n descrip on of the Company's compensa on principles and amounts for the members of the Execu ve/n Commi ee can be found in the 2024 compensa on report./n 5.3. Consulta ve vote on the 2024 Compensa on Report/n The Board of Directors proposes that the General Mee ng approve, on a consulta ve basis, the/n compensa on report for the 2024 financial year./n Explana on: Pursuant to ar cle 735 para. 3 item 4 CO, the Board of Directors submits the compensa on/n report to the General Mee ng for a consulta ve vote./n6. Re-elec on of the Independent Vo ng Rights Representa ve/n The Board of Directors proposes the re-elec on of Mr. Thomas Hua, esq., partner at gbf Avocats SA, Route/n de Pré-Bois 20, 1215 Genève Aéroport, Switzerland, as independent proxy of the Company for another term/n of office un l the conclusion of the next Annual General Mee ng./n Explana on: Pursuant to ar cle 698 para. 3 item 3 CO, the General Mee ng is responsible for the above/n elec on. Mr. Thomas Hua fulfills the legal requirements and is available for elec on./n7. Re-elec on of the Auditors/n The Board of Directors proposes the re-elec on of FORVIS MAZARS SA, Geneva, as the Company's statutory/n auditors for another term of office un l the conclusion of the next Annual General Mee ng./n Explana on: Pursuant to ar cl"